These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23795)

  • 1. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic melanocyte stimulating hormone release-inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover.
    Pugsley TA; Lippmann W
    Arzneimittelforschung; 1977; 27(12):2293-6. PubMed ID: 23796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 4. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
    Björkman S; Castensson S; Sievertsson H
    J Med Chem; 1979 Aug; 22(8):931-5. PubMed ID: 40028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of melanostatin on the central nervous system].
    Chepurnova NE; Borzenkov VM; Chepurnov SA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (2):36-42. PubMed ID: 6132624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the tripeptides TRH, MIF and MAF on the cerebral dopaminergic system.
    Klusha B; Georgiev V; Petkov V; Markovska V
    Acta Physiol Pharmacol Bulg; 1983; 9(2):14-9. PubMed ID: 6140814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIF (Pro-Leu-Gly-NH2): failure to affect oxotremorine effects in mice and rats as well as fluphenazine catalepsy or amphetamine hyperactivity in rats.
    Björkman S; Lewander T; Zetterström T
    J Pharm Pharmacol; 1980 Apr; 32(4):296-7. PubMed ID: 6103063
    [No Abstract]   [Full Text] [Related]  

  • 10. Possible association of increased rat behavioral effects and increased striatal dopamine and norepinephrine levels during the DOPA-potentiation test.
    Spirtes MA; Plotnikoff NP; Kostrzewa RM; Harston CT; Kastin AJ; Christensen CW
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):121-4. PubMed ID: 13411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure activity relationship studies with hypothalamic peptide hormones. I. Effect of melanotropin release inhibiting factor and analogs on tolerance to morphine in the rat.
    Bhargava HN; Kim HS
    J Pharmacol Exp Ther; 1982 Feb; 220(2):394-8. PubMed ID: 6120229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central action of melanostatin (MIF-1) in mice.
    Brus R; Szkilnik R; Stanosek B; Makowska B; Piguła J
    Acta Physiol Pol; 1984; 35(5-6):447-53. PubMed ID: 6152791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy.
    Maj J; Mogilnicka E; Przewlocka B
    Pharmacol Biochem Behav; 1975; 3(1):25-7. PubMed ID: 1168927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The action of psychotropic drugs on DOPA induced behavioural responses in mice.
    Berendsen H; Leonard BE; Rigter H
    Arzneimittelforschung; 1976; 26(9):1686-9. PubMed ID: 11809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-dopa potentiating analogs of Pro-Leu-Gly-NH2 with oral efficacy.
    Albrecht HP; Hofman HP; Klebe G; Kreiskott H
    Boll Chim Farm; 1991 Feb; 130(2):55-9. PubMed ID: 1678611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-Leu-Gly-NH2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouse.
    Mycroft FJ; Wei ET
    Peptides; 1984; 5(5):883-7. PubMed ID: 6150468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats.
    Hara C; Kastin AJ
    Pharmacol Biochem Behav; 1986 Jun; 24(6):1785-7. PubMed ID: 2874569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)].
    Schneider E; Fischer PA; Jacobi P; Reh W
    Arzneimittelforschung; 1978; 28(8):1296-7. PubMed ID: 37848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF).
    Plotnikoff NP; Kastin AJ; Anderson MS; Schally AV
    Life Sci I; 1971 Nov; 10(22):1279-83. PubMed ID: 4947365
    [No Abstract]   [Full Text] [Related]  

  • 20. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice.
    Huidobro-Toro JP; De Carolis AS; Longo VG
    Pharmacol Biochem Behav; 1974; 2(1):105-9. PubMed ID: 4364044
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.